Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOpredict-Lung neoadjuvant nivolumab with or without relatlimab in resectable NSCLC
NL-OMON60197Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and relatlimab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Universitätsmedizin Essen. Primary endpoint: Feasibility of curative-intent surgery. Started Jan 2022; status: completed.
02
Drugs
nivolumabrelatlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60197.